Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Sep;38(3):243–248. doi: 10.1111/j.1365-2125.1994.tb04348.x

The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.

N L Kerry 1, A A Somogyi 1, F Bochner 1, G Mikus 1
PMCID: PMC1364796  PMID: 7826826

Abstract

1. The enzyme kinetics of dextromethorphan O-demethylation in liver microsomes from three extensive metabolisers (EM) with respect to CYP2D6 indicated high (Km1 2.2-9.4 microM) and low (Km2 55.5-307.3 microM) affinity sites whereas microsomes from two poor metabolisers (PM) indicated a single site (Km 560 and 157 microM). Similar differences were shown for 3-methoxymorphinan O-demethylation to 3-hydroxymorphinan (Km 6.9-9.6 microM in EM subjects; Km 307 and 213 microM in PM subjects). 2. Dextromethorphan O-demethylation was inhibited competitively by quinidine (Ki 0.1 microM), rac-perhexiline (Ki 0.4 microM), dextropropoxyphene (Ki 6 microM), rac-methadone (Ki 8 microM), and 3-methoxymorphinan (Ki 15 microM). These compounds were also potent inhibitors of 3-methoxymorphinan O-demethylation with IC50 values ranging from 0.02-12 microM. Anti-LKM1 serum inhibited both dextromethorphan and 3-methoxymorphinan O-demethylations in a titre-dependent manner. 3. The Michaelis-Menten constant for dextromethorphan N-demethylation to 3-methoxymorphinan (Km 632-977 microM) and dextrorphan N-demethylation to 3-hydroxymorphinan (Km 1571-4286 microM) did not differ between EM and PM microsomes. These N-demethylation reactions were not inhibited by quinidine and rac-methadone or LKM1 antibodies. 4. Dextromethorphan and 3-methoxymorphinan are metabolised by the same P450 isoform, CYP2D6, whereas the N-demethylation reactions are not carried out by CYP2D6.

Full text

PDF
243

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Botsch S., Gautier J. C., Beaune P., Eichelbaum M., Kroemer H. K. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120–126. [PubMed] [Google Scholar]
  2. Broly F., Libersa C., Lhermitte M., Bechtel P., Dupuis B. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol. 1989 Jul;28(1):29–36. doi: 10.1111/j.1365-2125.1989.tb03502.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Broly F., Libersa C., Lhermitte M., Dupuis B. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol. 1990 Mar 15;39(6):1045–1053. doi: 10.1016/0006-2952(90)90283-q. [DOI] [PubMed] [Google Scholar]
  4. Chen Z. R., Somogyi A. A., Bochner F. Polymorphic O-demethylation of codeine. Lancet. 1988 Oct 15;2(8616):914–915. doi: 10.1016/s0140-6736(88)92529-9. [DOI] [PubMed] [Google Scholar]
  5. Chen Z. R., Somogyi A. A., Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit. 1990 Jan;12(1):97–104. doi: 10.1097/00007691-199001000-00018. [DOI] [PubMed] [Google Scholar]
  6. Cooper R. G., Evans D. A., Whibley E. J. Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet. 1984 Feb;21(1):27–33. doi: 10.1136/jmg.21.1.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dayer P., Desmeules J., Leemann T., Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun. 1988 Apr 15;152(1):411–416. doi: 10.1016/s0006-291x(88)80729-0. [DOI] [PubMed] [Google Scholar]
  8. Dayer P., Leemann T., Striberni R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther. 1989 Jan;45(1):34–40. doi: 10.1038/clpt.1989.6. [DOI] [PubMed] [Google Scholar]
  9. Fischer V., Vogels B., Maurer G., Tynes R. E. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther. 1992 Mar;260(3):1355–1360. [PubMed] [Google Scholar]
  10. Gueguen M., Meunier-Rotival M., Bernard O., Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med. 1988 Aug 1;168(2):801–806. doi: 10.1084/jem.168.2.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Henthorn T. K., Spina E., Dumont E., von Bahr C. In vitro inhibition of a polymorphic human liver P-450 isozyme by narcotic analgesics. Anesthesiology. 1989 Feb;70(2):339–342. doi: 10.1097/00000542-198902000-00025. [DOI] [PubMed] [Google Scholar]
  12. Jacqz-Aigrain E., Funck-Brentano C., Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics. 1993 Aug;3(4):197–204. doi: 10.1097/00008571-199308000-00004. [DOI] [PubMed] [Google Scholar]
  13. Jaruratanasirikul S., Cooper A. D., Blaschke T. F. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin. Drug Metab Dispos. 1992 May-Jun;20(3):379–382. [PubMed] [Google Scholar]
  14. Kerry N. L., Somogyi A. A., Mikus G., Bochner F. Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes. Biochem Pharmacol. 1993 Feb 24;45(4):833–839. doi: 10.1016/0006-2952(93)90166-t. [DOI] [PubMed] [Google Scholar]
  15. Kronbach T., Mathys D., Gut J., Catin T., Meyer U. A. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem. 1987 Apr;162(1):24–32. doi: 10.1016/0003-2697(87)90006-6. [DOI] [PubMed] [Google Scholar]
  16. Küpfer A., Schmid B., Pfaff G. Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica. 1986 May;16(5):421–433. doi: 10.3109/00498258609050249. [DOI] [PubMed] [Google Scholar]
  17. Larrey D., Amouyal G., Tinel M., Letteron P., Berson A., Labbe G., Pessayre D. Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol. 1987 Nov;24(5):676–679. doi: 10.1111/j.1365-2125.1987.tb03230.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mikus G., Somogyi A. A., Bochner F., Eichelbaum M. Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochem Pharmacol. 1991 Mar 1;41(5):757–762. doi: 10.1016/0006-2952(91)90077-i. [DOI] [PubMed] [Google Scholar]
  19. OMURA T., SATO R. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. J Biol Chem. 1964 Jul;239:2379–2385. [PubMed] [Google Scholar]
  20. Pfandl B., Mörike K., Winne D., Schareck W., Breyer-Pfaff U. Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotica. 1992 Jun;22(6):721–730. doi: 10.3109/00498259209053134. [DOI] [PubMed] [Google Scholar]
  21. Sanz E. J., Bertilsson L. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo. Ther Drug Monit. 1990 May;12(3):297–299. doi: 10.1097/00007691-199005000-00016. [DOI] [PubMed] [Google Scholar]
  22. Schmid B., Bircher J., Preisig R., Küpfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther. 1985 Dec;38(6):618–624. doi: 10.1038/clpt.1985.235. [DOI] [PubMed] [Google Scholar]
  23. Shah R. R., Oates N. S., Idle J. R., Smith R. L., Lockhart J. D. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):295–299. doi: 10.1136/bmj.284.6312.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Vetticaden S. J., Cabana B. E., Prasad V. K., Purich E. D., Jonkman J. H., de Zeeuw R., Ball L., Leeson L. J., Braun R. L. Phenotypic differences in dextromethorphan metabolism. Pharm Res. 1989 Jan;6(1):13–19. doi: 10.1023/a:1015835215945. [DOI] [PubMed] [Google Scholar]
  25. Wu D., Otton S. V., Morrow P., Inaba T., Kalow W., Sellers E. M. Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. J Pharmacol Exp Ther. 1993 Aug;266(2):715–719. [PubMed] [Google Scholar]
  26. Wu D., Otton S. V., Sproule B. A., Busto U., Inaba T., Kalow W., Sellers E. M. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol. 1993 Jan;35(1):30–34. doi: 10.1111/j.1365-2125.1993.tb05666.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Yue Q. Y., Svensson J. O., Alm C., Sjöqvist F., Säwe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol. 1989 Dec;28(6):639–645. doi: 10.1111/j.1365-2125.1989.tb03556.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Zanger U. M., Hauri H. P., Loeper J., Homberg J. C., Meyer U. A. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci U S A. 1988 Nov;85(21):8256–8260. doi: 10.1073/pnas.85.21.8256. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES